Related Experiment Video
Updated: Jan 28, 2026
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice
Michael X Henderson1, Medha Sengupta1, Ian McGeary1
1Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, 3600 Spruce St, 3rd Floor Maloney, Philadelphia, PA, 19104-4283, USA.
Abstract:
Mutations in leucine-rich repeat kinase 2 (LRRK2) are one of the most common causes of familial Parkinson's disease (PD). The most common mutations in the LRRK2 gene induce elevated kinase activity of the LRRK2 protein. Recent studies have also suggested that LRRK2 kinase activity may be elevated in idiopathic PD patients, even in the absence of LRRK2 mutations. LRRK2 is therefore a prime candidate for small molecule kinase inhibitor development. However, it is currently unknown how LRRK2 influences the underlying pathogenesis of PD and how LRRK2 might influence extant pathogenesis. To understand whether LRRK2 inhibition would show some benefit in the absence of LRRK2 mutations, we treated a preclinical mouse model of PD with the potent LRRK2 inhibitor MLi-2. The inhibitor was well-tolerated by mice and dramatically reduced LRRK2 kinase activity. However, LRRK2 inhibition did not reverse motor phenotypes, pathological α-synuclein accumulation or neuron loss. The current study suggests that LRRK2 is not necessary for α-synuclein pathogenesis in this mouse model of PD and that further studies are needed to assess the likely clinical benefit of LRRK2 inhibition in idiopathic PD.
Insights
LRRK2 kinase inhibitors did not reverse Parkinson's disease symptoms in a preclinical model. This suggests LRRK2 may not be essential for alpha-synuclein pathology in Parkinson's disease.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial Parkinson's disease (PD).
- Elevated LRRK2 kinase activity is implicated in both familial and idiopathic PD.
- LRRK2 is a potential therapeutic target for Parkinson's disease.
Purpose of the Study:
- To investigate the therapeutic potential of LRRK2 inhibition in Parkinson's disease pathogenesis.
- To determine if LRRK2 kinase activity is essential for alpha-synuclein accumulation and neurodegeneration.
- To assess the efficacy of LRRK2 inhibition in a preclinical mouse model of PD.
Main Methods:
- Treatment of a preclinical mouse model of Parkinson's disease with the LRRK2 inhibitor MLi-2.
- Assessment of MLi-2's tolerability and its effect on LRRK2 kinase activity.
- Evaluation of motor phenotypes, alpha-synuclein aggregation, and neuron loss.
Main Results:
- The LRRK2 inhibitor MLi-2 was well-tolerated and effectively reduced LRRK2 kinase activity.
- MLi-2 treatment did not reverse motor deficits in the PD mouse model.
- Inhibition of LRRK2 did not alter pathological alpha-synuclein accumulation or prevent neuron loss.
Conclusions:
- LRRK2 kinase activity may not be a critical driver of alpha-synuclein pathogenesis in this PD model.
- LRRK2 inhibition might not be a universally effective therapeutic strategy for all forms of Parkinson's disease.
- Further research is required to clarify the role of LRRK2 in idiopathic PD and its potential clinical benefit.
Related Concept Videos
00:53Transgenic Organisms
00:46Feedback Inhibition
02:31Protection of Alcohols
Protection
It defines a protecting group as the masking agent to make the more reactive species inert to a given set of conditions. This concept is depicted via the illustration of liquid flow through different outlets in an assembly of pipes. The analogy helps to understand the role...
01:16Zones of Protection
Protective zones are defined by closed dashed lines, containing one or more components. A key characteristic of these zones is the strategic placement of...
01:23Radial System Protection
In a radial system with a fault downstream of the third breaker, ideally, only the third breaker will open, isolating the fault and interrupting the load connected beyond it. The second breaker has a longer delay setting,...
01:27Protecting Self-Esteem